Company intelligence / Profile preview
Cellvation
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Cellvation has two Phase 2 randomized, double-blind, placebo-controlled studies ongoing for autologous bone marrow-derived stem cells in severe traumatic brain injury - one in pediatric patients (up to 50 patients, NCT01851083) and one in adults (up to 55 patients, NCT02525432). Both studies are supported by approximately $10 million in grants from the National Institutes of Health and Department of Defense.
- Therapeutic areas
- Neurology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
The University of Texas Health Science Center at Houston
Beyond the preview
Go deeper on Cellvation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellvation.